Articles: sars-cov-2.
-
Background & objectives The COVID-19 pandemic underscores the significance of vaccination in mitigating disease spread, with Covishield and Covaxin serving as pivotal vaccines in India. Breast milk, rich in vital antibodies like IgA and IgG, plays a crucial role in enhancing the immune defence of breastfeeding infants. However, limited research exists on the antibody responses in breast milk among individuals receiving single versus double doses of the COVID-19 vaccine. ⋯ Interpretation & conclusions This study underscores the significance of COVID-19 vaccination in impacting IgA and IgG antibody presence in breast milk. Completing the double-dose regimen correlated with higher IgA and IgG levels, emphasizing the benefits of complete vaccination. These findings contribute to understanding vaccination's impact on maternal-infant health.
-
J. Korean Med. Sci. · Oct 2024
Multicenter StudyLong-Term Outcomes of COVID-19 and Risk Factors for Prolonged or Persistent COVID-19 in Lymphoma Patients: A Multicenter, Retrospective Cohort Study.
Patients with hematologic malignancies exhibit persistent severe acute respiratory syndrome coronavirus 2 positivity over long periods after coronavirus disease 2019 (COVID-19) diagnosis. However, the frequency of, risk factors for, and prognosis of prolonged COVID-19 in immunocompromised patients remain unclear. Therefore, we investigated the long-term outcomes of COVID-19 in lymphoma patients and identified the associated factors and impact of prolonged COVID-19 on mortality. ⋯ Prolonged COVID-19 was more frequent in lymphoma patients who received BR treatment followed by rituximab maintenance therapy and associated with unfavorable long-term outcomes and higher 1-year mortality.
-
J. Korean Med. Sci. · Oct 2024
Patient-Reported Adverse Events Among Elderly Patients Receiving Novel Oral COVID-19 Antivirals: A Nationwide Sampled Survey in Korea.
There is a dearth of research on the factors linked with adverse events (AEs) associated with nirmatrelvir/ritonavir (NMVr) and molnupiravir (MOL), particularly in the elderly. Therefore, this study aimed to investigate self-reported AEs and identify factors associated with the occurrence of AEs following NMVr or MOL treatment among survey participants aged 60 years or older in South Korea. ⋯ No AEs required further evaluation to change treatment strategies in elderly patients on NMVr or MOL. Several factors, including the use of MOL, history of COVID-19, and reported health status, were associated with an increased incidence of AEs. Both treatments may still be useful choices for patients with non-severe COVID-19 aged 60 years or older. However, close monitoring of unidentified potential harm and further investigation of the factors associated with the occurrence of AEs are needed.